Vedolizumab
Vedolizumab is a pharmaceutical drug with 82 clinical trials. Currently 19 active trials ongoing. Historical success rate of 79.2%.
Success Metrics
Based on 38 completed trials
Phase Distribution
Phase Distribution
8
Early Stage
15
Mid Stage
41
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
70.4%
38 of 54 finished
29.6%
16 ended early
19
trials recruiting
82
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)
Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis
Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
Clinical Trials (82)
Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)
Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis
Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis
Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis
The Association Between Interleukin-7 Receptor Gene Polymorphism and the Risk of Ulcerative Colitis
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio
EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis
Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma
Vedolizumab for the Treatment of Collagenous Gastritis
VedAryo® (Vedolizumab) Effectiveness and Safety Evaluation
Autologous Stem Cell Transplant for Crohn's Disease
Association Between Effectiveness of Mirikizumab and UC Patients With High Neutrophilic Infiltration in Epithelium of the Colonic Mucosa
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 82